
Catalent, Inc. – NYSE:CTLT
Catalent stock price monthly change
Catalent stock price quarterly change
Catalent stock price yearly change
Catalent key metrics
Market Cap | 11.52B |
Enterprise value | 16.25B |
P/E | 27.85 |
EV/Sales | 3.41 |
EV/EBITDA | 15.14 |
Price/Sales | 2.48 |
Price/Book | 2.41 |
PEG ratio | -3.02 |
EPS | -1.24 |
Revenue | 4.49B |
EBITDA | 338M |
Income | -227M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 8.62% |
Oper. margin | 13.77% |
Gross margin | 32.71% |
EBIT margin | 13.77% |
EBITDA margin | 7.52% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCatalent stock price history
Catalent stock forecast
Catalent financial statements
$63.5
Analysts Price target
Financials & Ratios estimates
Jun 2022 | 1.31B | 187M | 14.24% |
---|---|---|---|
Mar 2023 | 1.03B | -227M | -21.89% |
Jun 2023 | 1.06B | -86M | -8.05% |
Mar 2024 | 1.07B | -101M | -9.4% |
Payout ratio | 0% |
---|
2020 | 0.33% |
---|---|
2021 | 0.12% |
2022 | 0.02% |
2023 | |
2024 |
Dec 2022 | 11147000000 | 6.23B | 55.93% |
---|---|---|---|
Mar 2023 | 10830000000 | 6.12B | 56.57% |
Jun 2023 | 10782000000 | 6.14B | 57.01% |
Mar 2024 | 9879000000 | 6.26B | 63.45% |
Jun 2022 | 69M | -394M | 1M |
---|---|---|---|
Mar 2023 | -64M | -110M | -25M |
Jun 2023 | 203M | -128M | -51M |
Mar 2024 | 12M | -74M | 0 |
Catalent alternative data
Aug 2023 | 387 |
---|---|
Sep 2023 | 457 |
Oct 2023 | 499 |
Nov 2023 | 503 |
Dec 2023 | 511 |
Jan 2024 | 426 |
Feb 2024 | 363 |
Apr 2024 | 201 |
May 2024 | 213 |
Jun 2024 | 221 |
Jul 2024 | 219 |
Aug 2023 | 19,000 |
---|---|
Sep 2023 | 17,800 |
Oct 2023 | 17,800 |
Nov 2023 | 17,800 |
Dec 2023 | 18,000 |
Jan 2024 | 18,000 |
Feb 2024 | 18,000 |
Mar 2024 | 18,000 |
Apr 2024 | 18,000 |
May 2024 | 18,000 |
Jun 2024 | 18,000 |
Jul 2024 | 18,000 |
Catalent other data
Period | Buy | Sel |
---|---|---|
Mar 2024 | 0 | 387 |
Jun 2024 | 0 | 1401 |
Jul 2024 | 0 | 12919 |
Aug 2024 | 0 | 6964 |
Sep 2024 | 0 | 1994 |
Oct 2024 | 0 | 320 |
Nov 2024 | 0 | 2800 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | RYAN MICHELLE R director | Common Stock | 2,800 | $59.7 | $167,160 | ||
Sale | FERRARO JOSEPH ANTHONY officer: SVP, General Counsel, .. | Common Stock | 320 | $59.97 | $19,190 | ||
Sale | MCERLANE DAVID officer: Group President, Biolo.. | Common Stock | 1,994 | $59.97 | $119,580 | ||
Sale | HOPSON RICKY officer: Pres. BioProduct Deliv.. | Common Stock | 662 | $59.56 | $39,429 | ||
Sale | GUNTHER SCOTT officer: SVP, Quality & Reg. Af.. | Common Stock | 666 | $59.55 | $39,660 | ||
Sale | FERRARO JOSEPH ANTHONY officer: SVP, General Counsel, .. | Common Stock | 608 | $59.58 | $36,225 | ||
Sale | EVOLI LISA officer: SVP, Chief HR Officer | Common Stock | 3,859 | $59.67 | $230,267 | ||
Sale | GENNADIOS ARISTIPPOS officer: Group Pres. Pharma & C.. | Common Stock | 1,169 | $59.55 | $69,614 | ||
Sale | MASELLI ALESSANDRO director, officer.. | Common Stock | 9,088 | $58.76 | $534,011 | ||
Sale | HOPSON RICKY officer: Pres. BioProduct Deliv.. | Common Stock | 206 | $58.67 | $12,086 |
Quarter | Transcript |
---|---|
Q1 2024 15 Nov 2023 | Q1 2024 Earnings Call Transcript |
Q4 2023 29 Aug 2023 | Q4 2023 Earnings Call Transcript |
Q3 2023 12 Jun 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 7 Feb 2023 | Q2 2023 Earnings Call Transcript |
Avid Bioservices: A Unique Growth Story With Many Tailwinds And Catalysts
International Companies Drive Diabesity Innovation
Catalent Remains Overvalued
Danaher: A Lost Year
Strong Earnings, Troubled Stocks: 3 Companies That May Light Up Volatility Screens
Lifecore: Highly Skewed Special Situation
Catalent: How Concerned Should One Be?
Catalent: A Promising Upside Opportunity In Play Despite Current Woes
Catalent: Ready For Growth Despite A Tough Year, Falling Revenues And A Lawsuit
-
When is Catalent's next earnings date?
Unfortunately, Catalent's (CTLT) next earnings date is currently unknown.
-
Does Catalent pay dividends?
No, Catalent does not pay dividends.
-
How much money does Catalent make?
Catalent has a market capitalization of 11.52B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2.46% to 4.38B US dollars.
-
What is Catalent's stock symbol?
Catalent, Inc. is traded on the NYSE under the ticker symbol "CTLT".
-
What is Catalent's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Catalent?
Shares of Catalent can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Catalent's key executives?
Catalent's management team includes the following people:
- Mr. Alessandro Maselli Pres & Chief Operating Officer(age: 53, pay: $3,780,000)
- Mr. John R. Chiminski Chairman & Chief Executive Officer(age: 61, pay: $3,170,000)
- Mr. Steven L. Fasman Senior Vice President, Gen. Counsel & Corporation Sec.(age: 62, pay: $1,320,000)
- Ms. Karen A. Flynn Chief Commercial Officer(age: 62, pay: $1,150,000)
- Mr. Thomas P. Castellano Senior Vice President & Chief Financial Officer(age: 45, pay: $731,920)
-
How many employees does Catalent have?
As Jul 2024, Catalent employs 18,000 workers.
-
When Catalent went public?
Catalent, Inc. is publicly traded company for more then 11 years since IPO on 31 Jul 2014.
-
What is Catalent's official website?
The official website for Catalent is catalent.com.
-
Where are Catalent's headquarters?
Catalent is headquartered at 14 Schoolhouse Road, Somerset, NJ.
-
How can i contact Catalent?
Catalent's mailing address is 14 Schoolhouse Road, Somerset, NJ and company can be reached via phone at +7 325376200.
-
What is Catalent stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Catalent in the last 12 months, the avarage price target is $63.5. The average price target represents a null change from the last price of $0.
Catalent company profile:

Catalent, Inc.
catalent.comNYSE
17,000
Drug Manufacturers - Specialty & Generic
Healthcare
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Somerset, NJ 08873
CIK: 0001596783
ISIN: US1488061029
CUSIP: 148806102